Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older

NCT00652184 is registered in ClinicalTrials.gov with aRigen Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00652184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00652184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older
Lead sponsor
aRigen Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2008
Completion date
September 30, 2009
Enrollment
300 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster, postherpetic neuralgia